Biotech stocks Argenx and Immunovant surged Thursday — and Tourmaline fell — on a rival’s lackluster muscle disease drug study.

The post Argenx, Immunovant Soar — As Tourmaline Plummets — On A Rival’s Lackluster Test Results appeared first on Investor’s Business Daily.